For these reasons, amongst others, Tau has come increasingly into focus for AD therapeutics research as an alternative or complement to Aβ-targeted therapeutic approaches (Lovestone and Manji 2020; Soeda and Takashima 2020). The gene discussed is MAPT; the disease is Alzheimer disease.